Diabetes Mellitus, Type 2
Conditions
Brief summary
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.
Interventions
DRUGSemaglutide
All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
19 Years to No maximum
Inclusion criteria
* The decision to initiate treatment with commercially available Rybelsus has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study * The participant with T2DM is scheduled to start treatment with Rybelsus based on the clinical judgment of their treating physician as specified in the approved label in Korea * Informed consent is obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study * Male/female age greater than or equal to (\>=) 19 years at the time of signing informed consent
Exclusion criteria
* Participants who are or have previously been on Rybelsus therapy * Known or suspected hypersensitivity to Rybelsus, the active substance or any of the excipients * Previous participation in this study. Participation is defined as having given informed consent in this study * Female participant who is pregnant, breast-feeding or intends to become pregnant and is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by Korea regulation or practice) * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Family or personal history of multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number (Incidence) of adverse events (AEs) | From baseline (week 0) to 26 weeks | Measured as count of events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number (Incidence) of hypoglycaemia Level 3 or Level 2 | From baseline (week 0) to 26 weeks | Hypoglycaemia Level 3 or Level 2 according to American Diabetes Association (ADA) guideline 2020 refers to: 1) Level 2: Glucose less than (\<) 54 milligrams per deciliter (mg/dL) (3.0 millimoles per liter \[mmol/L\]); 2) Level 3: A severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycaemia. Measured as count of events. |
| Change in glycated haemoglobin (HbA1c) | From baseline (week 0) to 26 weeks | Measured in percentage (%). |
| Participants achieving HbA1c target <7.0% | At 26 weeks | Measured as count of participants (Yes/No). |
| Change in fasting blood glucose (FBG)/fasting plasma glucose (FPG) | From baseline (week 0) to 26 weeks | Measured in mg/dL. |
| Change in post prandial blood glucose (PPBG)/post prandial plasma glucose (PPPG) | From baseline (week 0) to 26 weeks | Measured in mg/dL. |
| Change in body weight | From baseline (week 0) to 26 weeks | Measured in kilogram (kg). |
| Dose of Rybelsus | At 26 weeks | Measured in milligrams per day (mg/day). |
Contacts
Primary ContactNovo Nordisk
Outcome results
None listed